34136-57-7

Basic information

• Product Name: 3-Ethylbenzonitrile
• Synonyms: 3-ETHYLBENZONITRILE;NSC 86573;3-ethylbenzenecarbonitrile;3-Ethylbenzonitril
• CAS NO: 34136-57-7
• Molecular Formula: C₉H₉N
• Molecular Weight: 131.17
• Product Categories: Nitrile
• Mol File: 34136-57-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 215.752 °C at 760 mmHg
• Flash Point: 84.02 °C
• Appearance: /
• Density: 0.98 g/cm³
• Vapor Pressure: 0.145mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Ethylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Ethylbenzonitrile(34136-57-7)
• EPA Substance Registry System: 3-Ethylbenzonitrile(34136-57-7)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 3276
• Hazardous Substances Data: 34136-57-7(Hazardous Substances Data)

Usage

General Description

3-Ethylbenzonitrile is an organic compound belonging to the group of aromatic nitriles. This chemical, also known as Benzonitrile, 3-ethyl, is characterized by a benzene ring structure with a nitrile and ethyl group. It appears as a colorless to pale yellow liquid and is soluble in alcohol and ether. Predominantly used in the preparation of other chemical derivatives, 3-Ethylbenzonitrile is a potential irritant and should be handled with appropriate safety measures. It has the molecular formula C9H9N and the CAS number 619-22-9.

InChI:InChI=1/C9H9N/c1-2-8-4-3-5-9(6-8)7-10/h3-6H,2H2,1H3

Upstream product

• 587-02-0 m-ethylaniline 
• 2725-82-8 1-bromo-3-ethylbenzene 
• 557-21-1 dicyanozinc 
• 100-41-4 ethylbenzene 
• 74-85-1 ethene 
• 6952-59-6 3-cyanobromobenzene 
• 69113-59-3 3-iodobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 7446-70-0 aluminium trichloride 
• 60-29-7 diethyl ether 
• 100-47-0 benzonitrile 
• 544-97-8 dimethyl zinc(II) 
• 28188-41-2 m-(bromomethyl)benzonitrile 

Downstream Products

• 500293-87-8 3-ethylbenzamide 
• 619-20-5 m-ethylbenzoic acid 
• 2229-07-4 methyl radical 
• 61142-85-6 m-cyanobenzyl radical 
• 266317-44-6 2-(3-ethyl-phenyl)-4,5-dihydro-1H-imidazole 
• 500024-73-7 3-ethyl-N-hydroxy-benzamidine 
• 67273-59-0 2-(3-ethylphenyl)-1H-benzimidazole 
• 6136-68-1 3-acethylbenzonitrile 
• 903556-06-9 C₁₄H₂₁NO₂ 

Relevant articles and documents

Dual Ligand-Enabled Nondirected C-H Cyanation of Arenes

Aromatic nitriles are key structural units in organic chemistry and, therefore, highly attractive targets for C-H activation. Herein, the development of an arene-limited, nondirected C-H cyanation based on the use of two cooperatively acting commercially available ligands is reported. The reaction enables the cyanation of arenes by C-H activation in the absence of directing groups and is therefore complementary to established approaches.

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.